Wells Fargo analyst Derek Archila lowered the firm’s price target on Kezar Life Sciences (KZR) to $7 from $9 and keeps an Equal Weight rating on the shares. The firm thinks zetomipzomib demonstrated interesting signs of activity in autoimmune hepatitis, though some of the baseline imbalances worry Wells as well as the lack of a clear reg path for the indication as a whole. The firm remains on the sidelines.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue